{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117212","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.716125+00:00","generated_at":"2026-06-08T04:42:32.543646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cara Therapeutics Q3 2023 net loss $28M; cash runway extended into 2025 via $40M royalty financing","bullets":["Q3 total revenue $4.9M, down from $10.8M YoY; net loss $0.52/share vs $0.43/share YoY.","Cash $83.3M at Sep 30, 2023; entered $40M royalty financing with HealthCare Royalty to extend runway into 2025.","KORSUVA injection net sales $4.4M; vial orders up 36% QoQ; CMS confirmed TDAPA period until Mar 31, 2024.","Topline data from KIND 1 Phase 3 atopic dermatitis expected Dec 2023; KICK Phase 3 results in 2H24."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117212","json":"https://secwatch.observer/filing/0001104659-23-117212.json","markdown":"https://secwatch.observer/filing/0001104659-23-117212.md","text":"https://secwatch.observer/filing/0001104659-23-117212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923117212/0001104659-23-117212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923117212/tm2330513d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:42:32.543646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e94150de4ddbf69e9ea10e2a40593a4119a644e3","claim":"Tvardi Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $4.9 million, net income $28.0 million, or $(0.52) per basic and diluted share, EPS $(0.52) per basic and diluted share.","evidence_excerpt":"For the third quarter of 2023, net loss was $28.0 million, or $(0.52) per basic and diluted share, compared to net loss of $23.2 million, or $(0.43) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $4.9 million and $10.8 million for the three months ended September 30, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923117212/0001104659-23-117212-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$4.9 million"},{"label":"Net income","value":"$28.0 million, or $(0.52) per basic and diluted share"},{"label":"EPS","value":"$(0.52) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}